Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: PPD 1Q10 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: PPD 1Q10

Development segment revenue was $323.8 million (-3%) and income from operations was $36.8 million, compared to $62.6 million in 1Q09.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PPD 1Q10

1Q Revenues: $346.8 million (-5%)

1Q Earnings: $26.1 million (earnings were $66.6 million in 1Q09)

Comments: Development segment revenue was $323.8 million (-3%) and income from operations was $36.8 million, compared to $62.6 million in 1Q09. Discovery sciences revenue was $0.3 million, compared to $5.2 million in 1Q09. Revenue for this segment in 1Q09 included two milestone payments from Janssen-Cilag totaling $5.0 million for regulatory approvals of Priligy. Discovery sciences loss from operations was $10.7 million, compared to income of $4.0 million in 1Q09, primarily due to lower revenue, an increase in R&D expenses from the two compounds in-licensed from Janssen Pharmaceutica, and expenses related to the spin-off of the company’s compound partnering business. Gross authorizations for the quarter totaled $607.1 million. Backlog at March 31, 2010, was $3.1 billion and contract cancellations and adjustments were $127.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters